dp

DP-1 hydrochloride is a degradation product of SDC-TRAP-0063, a fragment of Ganetespib, a heat shock protein 90 (HSP90) inhibitor with antitumor activity.

Fructo-oligosaccharide DP11/GF10 is a fructooligosaccharide (FOS) compound with a degree of polymerization (DP) equal to 11. FOS consists of 10 fructose units connected by (2→1)-β-glycosidic bonds, with a single D-glucosyl unit present at the non-reducing end.

DP-B 99 (DP-B 99, DP-BAPTA-99, DPB-99, DP-BAPTA-99) is a potential chelating agent for the treatment of acute pancreatitis.

DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP[1]. DP-C-4 (1-50 μM; 24 hours) has degradation effects on EGFR and PARP simultaneously in a dose-dependent manner in SW1990 cells[1]. [1]. Mengzhu Zheng, et al. Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP. J Med Chem. 2021 May 26.

DP-1, a Ganetespib degradation product, represents a fragment derived from SDC-TRAP-0063. Ganetespib itself functions as an inhibitor of heat shock protein 90 (HSP90), exhibiting notable anti-tumor properties.

Dp2mT is an iron chelator which inhibits HIV-1 transcription.

Fructo-oligosaccharide DP12/GF11 is a member of fructooligosaccharides (FOS) characterized by a degree of polymerization (DP) of 12. FOS compounds consist of 11 fructose units connected by (2→1)-β-glycosidic bonds, with a lone D-glucosyl unit located at the non-reducing end.

DP 432 is an insulin hexapeptide fragment.

Fructo-oligosaccharide DP7/GF6 (Fructoheptasaccharide) belongs to fructooligosaccharides (FOS) with degree of polymerization (DP=7).

Dp44mT, a effective iron chelator, has selective antitumor activity.

Fructo-oligosaccharide DP9/GF8 (Fructo-oligosaccharide DP9 / GF8) belongs to fructooligosaccharides (FOS) with the degree of polymerization (DP=9).

Fructo-oligosaccharide DP8/GF7 (Fructo-oligosaccharide DP8 / GF7) is a fructooligosaccharide (FOS) with a degree of polymerization (DP=8). It consists of seven fructose units connected by (2→1)-β-glycosidic bonds, featuring a single D-glucosyl unit at the non-reducing end.

AH 6809 is an antagonist of EP and DP receptors, with Ki values of 1217, 1150, 1597, and 1415 nM for the cloned human EP1, EP2, EP3-III, and DP receptors, respectively, and a Ki of 350 nM for the mouse EP2 receptor.

AMG-009 is a selective and potent dual antagonist of CRTH2 and DP, with an IC50 value of 3 nM for CRTH2 and 12 nM for DP receptors.

PGD2-IN-1 (PGD2-inhibitor) is an effective DP receptor antagonist (IC50:0.3 nM), a compound that can inhibit prostaglandin D2 (PGD2) signaling. PGD2-IN-1 specifically targets and regulates the activity of PGD2 receptors or enzymes involved IN PGD2 synthesis or metabolism.

Tenofovir diphosphate TEA (TFV-DP TEA) is the triethylamine salt of TFV-DP, an ATP-competitive DNA polymerase inhibitor that inhibits HIV-1 reverse transcriptase. It has anti-HIV/HBV potential through its incorporation into the viral DNA strand to terminate viral DNA synthesis and thus inhibit viral genome replication.

BW 245C is a selective prostaglandin-like DP receptor (DP1) agonist, a prostaglandin analogue with inhibitory effects on the aggregation response of collagen, which can be used to study diseases such as stroke.

Laropiprant (MK-0524) is a potent and selective antagonist of prostaglandin D2 (PGD2) receptor (DP) such as and DP/DP1 receptor(Ki = 0.57 nM) and TP Receptor(Ki = 2.95 nM).

L 888607 is an effective and selective CRTH2 agonist (Ki: 0.8 nM).

L 888607 Racemate is a selective antagonist of the prostaglandin D2 receptor subtype 1 (DP1) with Ki values of 132 nM and 17 nM for DP1 and the thromboxane A2 receptor (TP), respectively.

Clofarabine-5'-diphosphate (Clofarabine-DP) is a metabolite resulting from the phosphorylation of Clofarabine by deoxycytidine kinase (dCK). It can undergo further phosphorylation to become Clofarabine-5'-triphosphate, exhibiting cytotoxicity in cancer cells by inhibiting DNA synthesis and repair.

Clofarabine-5'-diphosphatetrisodium (Clofarabine-DP trisodium) is the sodium salt form of Clofarabine-5'-diphosphate. As a metabolic product of Clofarabine, it results from phosphorylation by deoxycytidine kinase (dCK). Clofarabine-5'-diphosphate trisodium can undergo further phosphorylation to form Clofarabine-5'-triphosphate, demonstrating cytotoxicity in cancer cells by inhibiting DNA synthesis and repair.

Becocalcidiol(QRX-101, DP-006, COL-121) is a potential vitamin D analog for the treatment of psoriasis.

Nafagrel hydrochloride is a thromboxane A2 synthetase inhibitor.